Inventiva (IVA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Inventiva, a clinical-stage biopharmaceutical company, has reported its total voting rights and shares forming its capital as of November 4, 2024. The company is actively advancing its lead product candidate, lanifibranor, in a Phase 3 clinical trial for MASH/NASH treatment and holds a robust pipeline with additional drug candidates. As a public company listed on Euronext Paris and Nasdaq, Inventiva continues to explore further development opportunities in its field.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
